Leuven (BELGIUM) – May 4, 2017, 07:00h CEST – TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, is honoured to announce that the positive 52-week results from its Cx601 ADMIRE-CD Phase III clinical trial for the treatment of complex perianal fistulas in patients with Crohn’s disease will be presented at the 2017 Digestive Disease Week (DDW) annual meeting taking place from May 6-9 in Chicago, IL, USA.
The long-term results will be presented by Professor Julian Panés, Head of the Gastroenterology Department, at the Hospital Clinic of Barcelona (Spain) and President of the European Crohn’s and Colitis Organization (ECCO), at the DDW session dedicated to Controlled Clinical Trials in Inflammatory Bowel Diseases.
Lecture presentation title: Cx601, Allogeneic Expanded Adipose-Derived Mesenchymal Stem Cells (eASC), For Complex Perianal Fistulas In Crohn’s Disease: Long-Term Results From A Phase III Randomized Controlled Trial
Lecture presentation time and venue: May 9, 2017 from 11:15 AM to 11:30 AM (CT) at the Conference Center, McCormick Place, Chicago, IL.
The DDW annual meeting is one of the foremost GI events and the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
“We are delighted that the positive 52-week results from the ADMIRE-CD Phase III trial demonstrating the long-term safety and efficacy of Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients will be presented at a dedicated lecture at the DDW,” said Dr. Marie Paule Richard, Chief Medical Officer at TiGenix. “The DDW is one of the most prestigious congresses in GI. We are honoured that these data will be presented to the US medical community, a key milestone in the preparation for the launch of our global pivotal Phase III trial in the first half of 2017.”
TiGenix will also be hosting a key opinion leader (KOL) event at the Westin Chicago River North on May 8 2017 from 5:00 PM to 6:00 PM (CT), where leading experts in the GI field will discuss the unmet medical need in treating complex perianal fistulas, review the clinical data of Cx601, and provide insight into why Cx601 has the potential to become a breakthrough therapy in the management of complex perianal fistulas in patients with Crohn’s disease.
Speakers include:
• Dr. William J. Sandborn, MD, Professor of Medicine and Adjunct Professor of Surgery Chief, Division of Gastroenterology Vice Chair for Clinical Operations, Department of Medicine Director, UCSD IBD Center University of California San Diego and UC San Diego Health System
• Dr. Julian Panes, Chief of Department of Gastroenterology, Hospital Clinic de Barcelona and President of the European Chron’s and Colitis Organization
• Uthra Sundaram, VP GI Therapeutic Area, Global Commercial Leader, Takeda Pharmaceuticals
The event will be introduced and chaired by:
• Dr. Marie Paule Richard, Chief Medical Officer, TiGenix
Interested parties can follow the presentations of the KOL event via a webcast that can be accessed through http://www.wsw.com/webcast/cc/tig
For more information
Claudia D’Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com
